Tempus AI shares rally almost 6% after FDA clearance and solid revenue report fuel fresh buying

Traders Union
All News
Stocks
Tempus AI surges 5.68% today

Highlights

Tempus AI received FDA clearance for a product, adding to recent activity in its shares from insider sales and profit-taking.
The company posted $1.27 billion in annual revenue and a net loss of $245.03 million for the period.
Tempus AI stock trades near session highs with bullish momentum, forecasted to remain within $60.88 to $78.99 over the next five sessions.

Insider selling and FDA news drive renewed market focus

Tempus AI experienced increased attention after recent insider share sales and profit-taking followed a multi-day rally. The company received FDA clearance for one of its products. It reported annual revenue of $1.27 billion and a net loss of $245.03 million for the period.

Anton Kharitonov, expert at Traders Union, sees the current rally in Tempus AI as technically strong, but thinks risks are mounting. He notes insider selling and a net loss of $245.03 million remain concerns despite the bullish intraday momentum. The alignment of the 50-day and 200-day moving averages underlines persistent weakness in the longer-term trend. Kharitonov believes overbought oscillators and sharp volatility signal excessive optimism. "Despite today’s upside move, I remain skeptical — these technical and fundamental red flags limit sustainable upside for TEM in the near term."

Viktoras Karapetjanc, expert at Traders Union, highlights strong opportunities in Tempus AI following FDA product clearance and robust revenue growth. He sees the persistent bullish structure above key moving averages as a foundation for further gains. Karapetjanc points out renewed investor enthusiasm and technical momentum indicators that support the case for more upside. "With momentum building and a favorable regulatory backdrop, I expect the bullish structure to remain intact — further growth is likely in the coming sessions."

Sholanke Dele, market strategist, views the buying in Tempus AI as sentiment-driven and sees clear signs of overheating. He warns that recent profit-taking and intraday volatility reflect nervousness beneath the headline gains. Dele emphasizes that downside risk remains if momentum fades or if the stock loses near-term support. "Traders should be wary — when intraday volatility is this high, a sharp reversal can happen fast."

Bullish signals dominate as overbought risks and divergence emerge

Tempus AI is trading well above the 20-day, 50-day, and 200-day moving averages at $52.5, $52.99, and $56.69, respectively, confirming bullish momentum in short-, medium-, and long-term trends. The nearest resistance is the near-term ceiling at $69.95, with support at the near-term floor of $63.61. The longer-term trend context remains bearish, as indicated by the MA-50 vs MA-200 alignment. Momentum signals remain mostly bullish: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both point to continued buying pressure. The Relative Strength Index (RSI) at 63.97 is in bullish territory, although the Commodity Channel Index (CCI) at 156.32 and Bull/Bear Power (BBP) at 11.77 both indicate overbought conditions and that buyers currently dominate intraday momentum. The Stochastic RSI, at 64.54, signals a strong sell, in conflict with stronger upward momentum readings, creating a clear divergence. Price is up $3.76 or 5.68% today, opening with a moderate upside gap of $0.28 (0.42%), trading near the session high, and posting intraday volatility of 9.97%. The Awesome Oscillator (AO) supports the bullish bias, and intraday price action confirms strength toward session highs.

Previously it was reported that Tempus AI demonstrated robust operational and technical momentum, with analysts highlighting sustained buying strength but cautioning about overbought conditions. The current analysis adds a layer of nuance by noting lingering profit-taking and insider sales alongside continued bullish signals, with key levels at $63.61 and $69.95 now critical for assessing near-term direction.

Source of Data: TEM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.